Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation

Khanolkar, M., Morris, R. H. K., Thomas, A. W., Bolusani, H., Roberts, A. W., Green, J., Jackson, S. K. and Evans, L. M. (2008) Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation. Atherosclerosis, 197 (2). pp. 718-724. ISSN 0021-9150

Full text not available from this repository

Publisher's URL: http://dx.doi.org/10.1016/j.atherosclerosis.2007.0...


Item Type:Article
Uncontrolled Keywords:type 2 diabetes mellitus, rosiglitazone, platelets
Faculty/Department:Faculty of Health and Applied Sciences
ID Code:7138
Deposited By: H. Hammond
Deposited On:16 Jul 2010 08:02
Last Modified:12 Aug 2013 07:59

Request a change to this item

Copyright 2013 © UWE better together